secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001437749-25-030184
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences stockholders approve equity plan amendment and ratify director options
--------------------------------------------------------------------------------

- Stockholders approved increasing Equity Plan shares by 2 million and changing Consultant definition.
- Ratified options for up to 1.1 million shares, including 600,000 to directors (CEO LaViolette).
- Director options have exercise price $15.65, 10-year term, vesting over annual meeting and monthly.
- Proposal 1 voted 50,247,945 For vs 2,753,901 Against; Proposal 2 similarly approved.
- Special Meeting held Sept 30, 2025; quorum of 53,011,701 shares represented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925030184/0001437749-25-030184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774925030184/plse20250929_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-030184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer